232 related articles for article (PubMed ID: 29394468)
1. Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy.
Li YQ; Yin JY; Liu ZQ; Li XP
IUBMB Life; 2018 Mar; 70(3):183-191. PubMed ID: 29394468
[TBL] [Abstract][Full Text] [Related]
2. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
4.
Li YQ; Zhang XY; Chen J; Yin JY; Li XP
J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Smeazzetto S
IUBMB Life; 2017 Apr; 69(4):218-225. PubMed ID: 28164426
[TBL] [Abstract][Full Text] [Related]
7. Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs.
Petruzzelli R; Polishchuk RS
Cells; 2019 Sep; 8(9):. PubMed ID: 31540259
[TBL] [Abstract][Full Text] [Related]
8. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
[TBL] [Abstract][Full Text] [Related]
11. Roles and mechanisms of copper transporting ATPases in cancer pathogenesis.
Zhang Y; Li M; Yao Q; Chen C
Med Sci Monit; 2009 Jan; 15(1):RA1-5. PubMed ID: 19114980
[TBL] [Abstract][Full Text] [Related]
12. ATP7A and ATP7B copper transporters have distinct functions in the regulation of neuronal dopamine-β-hydroxylase.
Schmidt K; Ralle M; Schaffer T; Jayakanthan S; Bari B; Muchenditsi A; Lutsenko S
J Biol Chem; 2018 Dec; 293(52):20085-20098. PubMed ID: 30341172
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
14. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
[TBL] [Abstract][Full Text] [Related]
15. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T
Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
17. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
[TBL] [Abstract][Full Text] [Related]
19. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
20. Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.
Vyas A; Duvvuri U; Kiselyov K
Biochem J; 2019 Dec; 476(24):3705-3719. PubMed ID: 31790150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
